目的 觀察咳喘順丸聯(lián)合沙美特羅替卡松吸入粉霧劑治療支氣管哮喘的臨床療效。方法 選擇2017年3月—2020年12月南陽醫(yī)學高等專科學校第一附屬醫(yī)院收治的98例支氣管哮喘患者，將患者按隨機數(shù)字表法分為對照組和治療組，每組各49例。對照組給予沙美特羅替卡松吸入粉霧劑，1泡/次，2次/d。治療組在對照組治療的基礎(chǔ)上口服咳喘順丸，5 g/次，3次/d。兩組均連續(xù)治療2周。觀察兩組療效，比較兩組臨床癥狀消失時間、肺功能指標和炎癥因子指標。結(jié)果 治療后，治療組的總有效率95.92%，對照組的總有效率73.47%，治療組的總有效率明顯高于對照組（P<0.05）。治療后，治療組的咳嗽、喘憋、肺部啰音消失時間均明顯短于對照組（P<0.05）。治療后，兩組第1秒用力呼氣容積（FEV₁）、最大呼氣流速（PEF）、用力肺活量（FVC）均較治療前升高（P<0.05），且治療組FEV₁、PEF、FVC高于對照組（P<0.05）。治療后，兩組患者干擾素-γ（IFN-γ）水平較治療前升高，白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）水平較治療前降低（P<0.05），且治療組IFN-γ水平高于對照組，IL-6、TNF-α水平低于對照組（P<0.05）。結(jié)論 咳喘順丸聯(lián)合沙美特羅替卡松吸入粉霧劑治療支氣管哮喘可促進癥狀緩解和肺功能改善，減輕機體炎癥反應(yīng)。

Objective To observe the clinical effect of Kechuanshun Pills combined with salmeterol and fluticasone in treatment of bronchial asthma. Methods Patients (98 cases) with bronchial asthma in the First Affiliated Hospital of Nanyang Medical College from March 2017 to December 2020 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were given Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 bubble/time, twice daily. Patients in the treatment group were po administered with Kechuanshun Pills on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the disappearance times of clinical symptoms, the pulmonary function index, and the inflammatory factor index in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.92%, that of the control group was 73.47%, and the total effective rate of the treatment group was significantly higher than that of the control group (P< 0.05). After treatment, the disappearance time of cough, wheezing, and pulmonary rale in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the FEV₁, PEF, and FVC in two groups were higher than those before treatment (P< 0.05), and the FEV₁, PEF, and FVC in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of IFN-γ in two groups were higher than those before treatment, while the levels of IL-6 and TNF-α were lower than those before treatment (P < 0.05). And the level of IFN-γ in the treatment group was higher than that in the control group, but the levels of IL-6 and TNF-α were lower than those in the control group (P < 0.05). Conclusion Kechuanshun Pills combined with salmeterol and fluticasone in the treatment of bronchial asthma can promote the remission of symptoms, the improvement of lung function, and reduce the body's inflammatory response.

R974

河南省醫(yī)學科技攻關(guān)計劃項目（2017T03241）